News
ISEE
39.95
0.00%
0.00
Abcam: Further Upside Limited With Potential Acquisition In The Making, Reiterate Hold
Seeking Alpha · 08/26/2023 15:58
Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation
Seeking Alpha · 08/16/2023 16:41
Paulson takes new stakes in Newmont, Iveric Bio and Madrigal in Q2
Seeking Alpha · 08/14/2023 21:57
BUZZ-Apellis falls after rival eye disease treatment wins FDA nod
Reuters · 08/07/2023 14:12
BRIEF-Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Reuters · 07/11/2023 23:01
*Astellas Completes Acquisition Of Iveric Bio >4503.TO ISEE
Dow Jones · 07/11/2023 23:00
Press Release: Astellas Completes Acquisition of Iveric Bio
Dow Jones · 07/11/2023 23:00
Iveric Bio Inc: Current report
Press release · 07/11/2023 18:03
Iveric Bio Inc: Amendments to 40 Act only filings
Press release · 07/11/2023 18:03
Iveric Bio Inc: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 07/11/2023 18:03
More
Webull provides a variety of real-time ISEE stock news. You can receive the latest news about Iveric Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ISEE
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).